Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?

被引:103
|
作者
Theron, Grant [1 ,2 ,3 ,4 ]
Venter, Rouxjeane [3 ,4 ]
Calligaro, Greg [1 ,2 ]
Smith, Liezel [1 ,2 ]
Limberis, Jason [1 ,2 ]
Meldau, Richard [1 ,2 ]
Chanda, Duncan [1 ,2 ,5 ]
Esmail, Aliasgar [1 ,2 ]
Peter, Jonny [1 ,2 ]
Dheda, Keertan [1 ,2 ,6 ]
机构
[1] Univ Cape Town, Lung Infect & Immun Unit, Div Pulmonol, Tygerberg, South Africa
[2] Univ Cape Town, Lung Inst, Dept Med, Tygerberg, South Africa
[3] Univ Stellenbosch, DST NRF Excellence Biomed TB Res, ZA-7505 Tygerberg, South Africa
[4] Univ Stellenbosch, MRC Ctr Mol & Cellular Biol, Div Mol Biol & Human Genet, Fac Med & Hlth Sci, ZA-7505 Tygerberg, South Africa
[5] Inst Med Res & Training, Lusaka, Zambia
[6] Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7925 Observatory, South Africa
基金
英国惠康基金; 英国医学研究理事会;
关键词
tuberculosis; diagnosis; Xpert; false positivity; PULMONARY TUBERCULOSIS; BACTERIAL LOAD; DIAGNOSIS; ASSAY; PERFORMANCE; GENEXPERT; BIOMARKER; SPECIFICITY; ACCURACY;
D O I
10.1093/cid/civ1223
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Patients with previous tuberculosis may have residual DNA in sputum that confounds nucleic acid amplification tests such as Xpert MTB/RIF. Little is known about the frequency of Xpert-positive, culture-negative ("false positive") results in retreatment patients, whether these are distinguishable from true positives, and whether Xpert's automated filter-based wash step reduces false positivity by removing residual DNA associated with nonintact cells. Methods. Pretreatment patients (n= 2889) with symptoms of tuberculosis from Cape Town, South Africa, underwent a sputum-based liquid culture and Xpert. We also compared Xpert results from dilutions of intact or heat-lysed and mechanically lysed bacilli. Results. Retreatment cases were more likely to be Xpert false-positive (45/321 Xpert-positive retreatment cases were false-positive) than new cases (40/461) (14% [95% confidence interval {CI}, 10%-18%]vs 8% [95% CI, 6%-12%]; P=.018). Fewer years since treatment completion (adjusted odds ratio [aOR], 0.85 [95% CI,.73-. 99]), less mycobacterial DNA (aOR, 1.14 [95% CI, 1.03-1.27]per cycle threshold [C-T]), and a chest radiograph not suggestive of active tuberculosis (aOR, 0.22 [95% CI,.06-. 82]) were associated with false positivity. C-T had suboptimal accuracy for false positivity: 46% of Xpert-positives with C-T > 30 would be false positive, although 70% of false positives would be missed. C-T's predictive ability (area under the curve, 0.83 [95% CI,.76-. 90]) was not improved by additional variables. Xpert detected nonviable, nonintact bacilli without a change in C-T vs controls. Conclusions. One in 7 Xpert-positive retreatment patients were culture negative and potentially false positive. False positivity was associated with recent previous tuberculosis, high C-T, and a chest radiograph not suggestive of active tuberculosis. Clinicians may consider awaiting confirmatory testing in retreatment patients with C-T > 30; however, most false positives fall below this cut-point. Xpert can detect DNA from nonviable, nonintact bacilli.
引用
收藏
页码:995 / 1001
页数:7
相关论文
共 50 条
  • [41] Xpert MTB/RIF Ultra-resistant and MTBDRplus-susceptible rifampicin results in people with tuberculosis: utility of FluoroType MTBDR and deep sequencing
    Ghebrekristos, Yonas
    Ahmed, Aysha
    Beylis, Natalie
    Singh, Sarishna
    Opperman, Christoffel
    Naufal, Fahd
    Folkerts, Megan
    Engelthaler, David
    Auma, Erick
    Venter, Rouxjeane
    Booley, Ghowa
    Metcalfe, John
    Warren, Robin
    Theron, Grant
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2025, 69 (03)
  • [42] Can we distinguish bipolar from unipolar depression: preliminary results
    Hranov, L. G.
    Simov, V.
    Hranov, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S405 - S405
  • [43] How we can utilize the Xpert MTB/RIF assay to decide on airborne infection isolation of inpatients with tuberculosis suspicion in Brazil: a brief review of the current data
    Resende, Mariangela Ribeiro
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2016, 20 (01): : 105 - 106
  • [44] The results of drug susceptibility testing of mycobacterium tuberculosis to rifampicin by Xpert® MTB / Rif, BACTEC MGIT 960 as compared with the method of seeding on solid nutrient media
    Morozova, Tatiana Ivanovna
    Salina, Tayiana
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [45] Detection of Mycobacterium tuberculosis and rifampicin resistance by Xpert® MTB/RIF assay among presumptive tuberculosis patients in Addis Ababa, Ethiopia from 2014 to 2021
    Diriba, Getu
    Alemu, Ayinalem
    Tola, Habteyes Hailu
    Eshetu, Kirubel
    Yenew, Bazezew
    Amare, Misikir
    Dagne, Biniyam
    Mollalign, Hilina
    Sinshaw, Waganeh
    Abebaw, Yeshiwork
    Seid, Getachew
    Tadesse, Mengistu
    Zerihun, Betselot
    Getu, Melak
    Moga, Shewki
    Meaza, Abyot
    Gamtesa, Dinka Fekadu
    Tefera, Zigba
    Wondimu, Amanuel
    Hailu, Michael
    Buta, Bedo
    Getahun, Muluwork
    Kebede, Abebaw
    IJID REGIONS, 2022, 5 : 97 - 103
  • [46] ROLE OF XPERT MTB/RIF IN DIFFERENTIATING TUBERCULOSIS FROM SARCOIDOSIS IN PATIENTS WITH MEDIASTINAL LYMPHADENOPATHY UNDERGOING EBUS-TBNA: A STUDY OF 147 PATIENTS
    Dhooria, Sahajal
    Gupta, Nalini
    Bal, Amanjit
    Sehgal, Inderpaul Singh
    Aggarwal, Ashutosh N.
    Sethi, Sunil
    Behera, Digambar
    Agarwal, Ritesh
    SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2016, 33 (03) : 258 - 266
  • [47] Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings
    Luetkemeyer, Anne F.
    Firnhaber, Cynthia
    Kendall, Michelle A.
    Wu, Xingye
    Mazurek, Gerald H.
    Benator, Debra A.
    Arduino, Roberto
    Fernandez, Michel
    Guy, Elizabeth
    Johnson, Pamela
    Metchock, Beverly
    Sattler, Fred
    Telzak, Edward
    Wang, Yun F.
    Weiner, Marc
    Swindells, Susan
    Sanne, Ian M.
    Havlir, Diane V.
    Grinsztejn, Beatriz
    Alland, David
    CLINICAL INFECTIOUS DISEASES, 2016, 62 (09) : 1081 - 1088
  • [48] Mixed Mycobacterium tuberculosis Complex Infections and False-Negative Results for Rifampin Resistance by GeneXpert MTB/RIF Are Associated with Poor Clinical Outcomes
    Zetola, Nicola M.
    Shin, Sanghyuk S.
    Tumedi, Kefentse A.
    Moeti, Keletso
    Ncube, Ronald
    Nicol, Mark
    Collman, Ronald G.
    Klausner, Jeffrey D.
    Modongo, Chawangwa
    JOURNAL OF CLINICAL MICROBIOLOGY, 2014, 52 (07) : 2422 - 2429
  • [49] Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia
    Alemu, Ayinalem
    Tadesse, Mengistu
    Seid, Getachew
    Mollalign, Helina
    Eshetu, Kirubel
    Sinshaw, Waganeh
    Abebaw, Yeshiwork
    Amare, Misikir
    Dagne, Biniyam
    Diriba, Getu
    Yenew, Bazezew
    Getu, Melak
    Zerihun, Betselot
    BMC INFECTIOUS DISEASES, 2020, 20 (01)
  • [50] Discordant results between genotypic and phenotypic assays (Xpert MTB/RIF vs. BACTEC MGIT 960 system) for detection of RIF-resistant Mycobacterium tuberculosis isolates in a high burden region
    Rafael, Laniado-Laborin
    Raquel, Muniz-Salazar
    Rogelio, Flores-Acosta
    Miroslava, Felix-Ponce
    Alejandra-Isabel, Jimenez-Gracia
    Saritzia Paola, Ruiz-Tamayo
    INFECTION GENETICS AND EVOLUTION, 2021, 96